Isoliquiritigenin Protects Against Diabetic Nephropathy in db/db Mice by Inhibiting Advanced Glycation End Product–Receptor for Advanced Glycation End Product Axis
Drug Development Research · 2025
DOI: 10.1002/ddr.70051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Qiwen Shi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Chalcones, Diabetic Nephropathies, Receptor for Advanced Glycation End Products. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: This work was supported by grants from the Zhejiang Provincial Natural Science Foundation of China (Nos. LTGD24C080001, LD22H090002), and the Natural Science F….
Abstract (Originalsprache)
Diabetes nephropathy (DN) is a severe diabetic chronic microvascular complication and the major cause of end‐stage renal disease (ESRD). Our study aimed to investigate the effects of isoliquiritigenin (ISL) a natural flavonoid compound on DN and to explore the underlying mechanisms. The db/db mice were received intragastric treatments of ISL (5, 10, or 20 mg/kg), vehicle or positive drug metformin (300 mg/kg) once a day for 12 weeks, and the db/m mice treated with vehicle were used as controls. ISL significantly ameliorated pathological changes and functional injury in the kidneys of db/db mice in a dose‐dependent manner. The administration of 20 mg/kg ISL reduced the levels of serum creatinine (Scr; 49.0 ± 1.7 vs. 56.9 ± 2.9 μmol/L; p < 0.01), blood urine nitrogen (BUN; 9.6 ± 1.3 vs. 12.0 ± 1.1 mmol/L; p < 0.05), albumin to creatinine ratio (ACR; 1925.8 ± 798.1 vs. 4269.4 ± 925.6 μg/mg; p < 0.01) and urinary albumin (276.2 ± 39.9 vs. 576.9 ± 108.9 μg; p < 0.05). Further study identified advanced glycation end product (AGE)–receptor for AGE (RAGE) axis as a target of ISL. ISL (20 mg/kg) lowered renal AGE level (2.5 ± 0.5 vs. 3.8 ± 0.6 μg/mg; p < 0.01) and RAGE expression, leading to improvements in renal fibrosis, oxidative stress, and inflammation. To sum up, our study demonstrated that ISL displayed preventive effects on the experimental model of DN through suppressing AGE–RAGE pathway, and provided some insights into the application of ISL in DN treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, Zhejiang, China.
ORCID-Profile: Qiwen Shi
Förderung
- This work was supported by grants from the Zhejiang Provincial Natural Science Foundation of China (Nos. LTGD24C080001, LD22H090002), and the Natural Science F…
Zitieren
APA
Shi, Q., Zhou, T., Hou, W., Zhou, Y., Deng, S., & Song, Y. (2025). Isoliquiritigenin Protects Against Diabetic Nephropathy in db/db Mice by Inhibiting Advanced Glycation End Product–Receptor for Advanced Glycation End Product Axis. Drug Development Research. https://doi.org/10.1002/ddr.70051
Vancouver
Shi Q, Zhou T, Hou W, Zhou Y, Deng S, Song Y. Isoliquiritigenin Protects Against Diabetic Nephropathy in db/db Mice by Inhibiting Advanced Glycation End Product–Receptor for Advanced Glycation End Product Axis. Drug Development Research. 2025. doi:10.1002/ddr.70051
BibTeX
@article{Shi2025,
author = {Shi, Qiwen and Zhou, Tao and Hou, Wenjun and Zhou, Yuqi and Deng, Shufen and Song, Ying},
title = {Isoliquiritigenin Protects Against Diabetic Nephropathy in db/db Mice by Inhibiting Advanced Glycation End Product–Receptor for Advanced Glycation End Product Axis},
journal = {Drug Development Research},
year = {2025},
doi = {10.1002/ddr.70051}
}
EUVIMED